John A Batsis1,2,3, William R Miranda4, Chaithra Prasad5, Maria L Collazo-Clavell6, Michael G Sarr7, Virend K Somers4, Francisco Lopez-Jimenez4. 1. Section of General Internal Medicine, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, USA. 2. Centers for Health and Aging, Dartmouth College, Hanover, New Hampshire, USA. 3. Geisel School of Medicine at Dartmouth and The Dartmouth Institute for Health Policy & Clinical Practice, Hanover, New Hampshire, USA. 4. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. 5. Division of Endocrinology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 6. Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, Minnesota, USA. 7. Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
AIM: Obesity is a major cardiovascular (CV) risk factor. Bariatric surgery (BSx) is an approved therapeutic alternative for class II-III obesity, but little evidence focuses on older adults. We assessed the effect of BSx on cardiometabolic variables and long-term CV risk in older adults. METHODS: We carried out a population-based, observational study from 1990-2009, of 40 consecutive elderly (age ≥60 years) residents of Olmsted County, MN, USA, with class II-III obesity treated with BSx at a University-based, academic health center. Data were obtained from the Rochester Epidemiology Project. Metabolic syndrome (MetS) was defined using American Heart Association/National Heart, Lung, Blood Institute (AHA/NHLBI) criteria (increased triglycerides, low high-density lipoprotein, increased blood pressure, increased glucose and body mass index as a modified measure of obesity instead of waist circumference). Change in CV risk factors, MetS prevalence, and impact on predicted CV risk using the Framingham risk score was ascertained at 1 year postoperatively and assessed statistically. RESULTS: Mean age and body mass index were 64.4 ± 3.7 and 45.0 ± 6.3 kg/m(2) , respectively, and 28 out of 40 (70%) were women. One participant died during the 11-month study period after BSx from respiratory complications related to BSx, and one participant died at 2 years. Percentage of excess weight loss decreased by 57.5% at 1 year. Prevalence 1 year after BSx decreased for diabetes (57.5% to 22.5%; P < 0.03), hypertension 87.5% to 73.7% (P = 0.003), dyslipidemia (80% to 42.5%; P < 0.001) and sleep apnea (62.5% to 23.7%; P < 0.001).MetS prevalence decreased from 80% to 45% (P < 0.002). Baseline risk was 14.1%, which changed at follow up at 8.2%. CONCLUSIONS: In older adults, BSx induces considerable weight loss, improves CV risk factors, decreases MetS prevalence and is an effective treatment in this population. Geriatr Gerontol Int 2016; 16: 618-624.
AIM: Obesity is a major cardiovascular (CV) risk factor. Bariatric surgery (BSx) is an approved therapeutic alternative for class II-III obesity, but little evidence focuses on older adults. We assessed the effect of BSx on cardiometabolic variables and long-term CV risk in older adults. METHODS: We carried out a population-based, observational study from 1990-2009, of 40 consecutive elderly (age ≥60 years) residents of Olmsted County, MN, USA, with class II-III obesity treated with BSx at a University-based, academic health center. Data were obtained from the Rochester Epidemiology Project. Metabolic syndrome (MetS) was defined using American Heart Association/National Heart, Lung, Blood Institute (AHA/NHLBI) criteria (increased triglycerides, low high-density lipoprotein, increased blood pressure, increased glucose and body mass index as a modified measure of obesity instead of waist circumference). Change in CV risk factors, MetS prevalence, and impact on predicted CV risk using the Framingham risk score was ascertained at 1 year postoperatively and assessed statistically. RESULTS: Mean age and body mass index were 64.4 ± 3.7 and 45.0 ± 6.3 kg/m(2) , respectively, and 28 out of 40 (70%) were women. One participant died during the 11-month study period after BSx from respiratory complications related to BSx, and one participant died at 2 years. Percentage of excess weight loss decreased by 57.5% at 1 year. Prevalence 1 year after BSx decreased for diabetes (57.5% to 22.5%; P < 0.03), hypertension 87.5% to 73.7% (P = 0.003), dyslipidemia (80% to 42.5%; P < 0.001) and sleep apnea (62.5% to 23.7%; P < 0.001).MetS prevalence decreased from 80% to 45% (P < 0.002). Baseline risk was 14.1%, which changed at follow up at 8.2%. CONCLUSIONS: In older adults, BSx induces considerable weight loss, improves CV risk factors, decreases MetS prevalence and is an effective treatment in this population. Geriatr Gerontol Int 2016; 16: 618-624.
Authors: John A Batsis; Abel Romero-Corral; Maria L Collazo-Clavell; Michael G Sarr; Virend K Somers; Lee Brekke; Francisco Lopez-Jimenez Journal: Obesity (Silver Spring) Date: 2007-03 Impact factor: 5.002
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: John A Batsis; Abel Romero-Corral; Maria L Collazo-Clavell; Michael G Sarr; Virend K Somers; Francisco Lopez-Jimenez Journal: Mayo Clin Proc Date: 2008-08 Impact factor: 7.616
Authors: J Fleischer; E M Stein; M Bessler; M Della Badia; N Restuccia; L Olivero-Rivera; D J McMahon; S J Silverberg Journal: J Clin Endocrinol Metab Date: 2008-07-22 Impact factor: 5.958
Authors: Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell Journal: N Engl J Med Date: 2007-06-07 Impact factor: 91.245
Authors: Fernando Mendonça; Maria Manuel Silva; Daniela Salazar; Maria João Ferreira; Jorge Pedro; Vanessa Guerreiro; Sara Viana; Joao Sérgio Neves; Sandra Belo; Ana Varela; Paula Freitas; Davide Carvalho Journal: Obes Facts Date: 2020-12-15 Impact factor: 3.942
Authors: Pedro R Pereira; Marta Guimarães; Tiago Morais; Sofia S Pereira; Mário Nora; Mariana P Monteiro Journal: Front Endocrinol (Lausanne) Date: 2018-11-28 Impact factor: 5.555